Skip to main content

22 - References

References

948 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 14 References

  1. EMC. Summary of Product Characteristics. 2024; http://www.medicines.org.uk/emc/.
  2. Baldwin D, et al. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-­analysis. BMJ 2011; 342:d1199.
  3. Bolam v Friern Barnet Hospital Management Committee [1957] 1 WLR582.
  4. Bolitho v City and Hackney Health Authority [1997] 3 WLR1151.
  5. British and Irish Legal Information Institute. Montgomery (Appellant) v Lanarkshire Health Board (Respondent) (Scotland). 2015; http://www.bailii.org/uk/cases/UKSC/2015/11.html.
  6. General Medical Council. Good practice in prescribing and managing medicines and devices. 2021 (last checked September 2024); https://www.gmc-­uk.org/guidance/ethical_guidance/14316.asp.
  7. Buckman Co. v. Plaintiffs’ Legal Comm. 531 U.S. 341. 2001; https://www.law.cornell.edu/supct/html/98-­1768.ZO.html.
  8. FindLaw. Off-­label use promotion is protected free speech. 2019 (last accessed September 2024); https://www.findlaw.com/legalblogs/second-­ circuit/off-­label-­use-­promotion-­is-­protected-­free-­speech/.
  9. Vijay A, et al. Patterns and predictors of off-­label prescription of psychiatric drugs. PLoS One 2018; 13:e0198363.
  10. Leslie DL, et al. Off-­label use of antipsychotic medications in Medicaid. Am J Manag Care 2012; 18:e109–117.
  11. Ishtiak-­Ahmed K, et al. Treatment indications and potential off-­label use of antidepressants among older adults: a population-­based descriptive study in Denmark. Int J Geriatr Psychiatry 2022; 37:10.1002/gps.5841.
  12. Martínez CE, et  al. Antidepressant use and off-­label prescribing in primary care in Spain (2013-­2018). An Pediatr (Engl Ed) 2022; 97:237–246.
  13. Hefner G, et  al. Off-­label use of antidepressants, antipsychotics, and mood-­stabilizers in psychiatry. J Neural Transm (Vienna) 2022; 129:1353–1365.
  14. Epstein RS, et al. The many sides of off-­label prescribing. Clin Pharmacol Ther 2012; 91:755–758.
  15. Wong J, et al. Off-­label indications for antidepressants in primary care: descriptive study of prescriptions from an indication based electronic prescribing system. BMJ 2017; 356:j603.
  16. Royal College of Psychiatrists. Use of licensed medicines for unlicensed applications in psychiatric practice (2nd edition) (CR210 Dec 2017). 2017 (last accessed September 2024); https://www.rcpsych.ac.uk/improving-­care/campaigning-­for-­better-­mental-­health-­policy/college-­ reports/2017-­college-­reports/use-­of-­licensed-­medicines-­for-­unlicensed-­applications-­in-­psychiatric-­practice-­2nd-­edition-­cr210-­dec-­2017.
  17. American Psychiatric Association. APA official actions: position statement on off-­label treatments. 2021 (last accessed September 2024); https://www.psychiatry.org/getattachment/053eae03-­9e23-­422f-­ab75-­2ea052eb6c81/Position-­Off-­Label-­Treatments.pdf.
  18. Royal Australian New Zealand College of Psychiatrists (RANZCP). ‘Off-­label’ prescribing in psychiatry. Professional Practice Guideline 4. 2023 (last accessed September 2024); https://www.ranzcp.org/getmedia/edc66b1d-­005b-­411d-­b277-­5c7fddc71ba2/ppg-­4-­off-­label-­prescribing-­ december-­2023.pdf.

No comments to display

Back to top